VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

rMCMV-TRP2
Vaccine Information
  • Vaccine Name: rMCMV-TRP2
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0004716
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Trp2 gene engineering:
    • Type: Recombinant vector construction
    • Description: An unmodified melanoma antigen, mouse tyrosinase-related protein 2 (TRP2), in mouse cytomegalovirus (MCMV) (Xu et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: An unmodified melanoma antigen, mouse tyrosinase-related protein 2 (TRP2), in mouse cytomegalovirus (MCMV)(Xu et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Prophylactic vaccination of the mice with a single dose of MCMV-TRP2 (Xu et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were subcutaneously (s.c.) challenged with 2 × 10^5 B16/F10 cells in 100 μl PBS in the shaved right flank (Xu et al., 2013).
  • Efficacy: Therapeutic vaccination with MCMV-TRP2 prolonged the survival of the mice challenged with B16 cells. Furthermore, vaccination with MCMV-TRP2 five months before tumor challenge still induced tumor rejection, which indicated that the vaccine induced long-term protection (Xu et al., 2013).
References
Xu et al., 2013: Xu G, Smith T, Grey F, Hill AB. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. Biochemical and biophysical research communications. 2013; 437(2); 287-291. [PubMed: 23811402].